FIBROBLAST GROWTH FACTOR 23 AND KLOTHO PROTEIN IN THE PATHOGENESIS OF SECONDARY HYPERPARATHYROIDISM
https://doi.org/10.14341/osteo2013320-27
Abstract
One of the main problems in patients with chronic kidney disease (CKD) is a disturbance of calcium-phosphorus metabolism, especially in chronic hemodialysis. Besides classical endocrine axis parathyroid-kidney, in recent years was established the existence of a new endocrine axis the bone-kidney, which gives a better explanation of the calcium and phosphorus metabolism abnormalities, pathophysiology of secondary hyperparathyroidism in CKD. FGF23 is a circulating factor synthesized in osteocytes. It inhibits renal phosphate reabsorption and activity of 1-alphahydroxylase. Anti-aging Klotho protein is a potent co-factor of FGF23. This review presents the mechanisms of the interaction of these elements of the newly discovered axis in normal settings and secondary hyperparathyroidism.
References
1. Bricker NS. On the pathogenesis of the uremic state. An exposition of the ‘trade-off hypothesis’. N Engl J Med 1972; 286 (20): 1093—1099.
2. Portale AA, Halloran BP, Murphy MM et al. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvi-tamin D by determining its production rate in humans. J Clin Invest 1986; 77 (1): 7—12.
3. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97 (11): 2534—2540.
4. Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int 2011; 79 (Suppl 121): S3—S8.
5. Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005; 187 (3): 311—325.
6. Kumar R, Thompson JR The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 2011;22(2):216—224.
7. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28 (4): 596—602.
8. Martin DR, Ritter CS, Slatopolsky E et al. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 2005; 289 (4): E729-E734
9. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. Journal of the American Society ofNephrology.2005; 16(2):520—528.
10. Hsu CY Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrology Dialysis Transplantation. 2002;17(8):1419—1425.
11. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International 2007; 71 (1): 31—38.
12. Murayama A, Takeyama K, Kitanaka S et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 1999;140(5):2224—2231.
13. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc NatlAcadSci USA 2001; 98 (11): 6500—6505.
14. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006 10;281(10):6120—6123.
15. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390(6655): 45—51.
16. Liu S, Vierthaler L, Tang W et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008; 19 (12): 2342—2350.
17. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24 (9): 3438—3450.
18. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278 (4): 2206—2211.
19. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19(3): 429—435.
20. Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91 (8): 3144—3149.
21. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21 (8): 1187—1196.
22. Lypez I, RodrHguez-Ortiz ME, AlmadMn Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80 (5): 475—482.
23. Tsujikawa H, Kurotaki x Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17 (12): 2393—2403.
24. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79 (12): 1370—1378.
25. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Journal of the American Society of Nephrology 2005; 16 (7):2205—2215.
26. Liu S, Quarles LD. How fibroblast growth factor 23 works. Journal of the American Society of Nephrology 2007;18 (6):1637—1647.
27. Prie D, Torres PU, Friedlander G. Latest findings in phosphate homeostasis. Kidney International 2009; 75 (9): 882—889.
28. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. Journal of the American Society of Nephrology 2010; 21 (9): 1427—1435.
29. Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. bq. Physiology 2009; 24 (1): 17—25.
30. Berndt T, Thomas LF, Craig TA et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci USA 2007; 104 (26): 11085—11090.
31. Martin DR, Ritter CS, Slatopolsky E et al. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 2005; 289 (4): E729—E734.
32. Ito N, Fukumoto S, Takeuchi Y et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF) 23 levels in humans. J Bone Miner Metab 2007; 25 (6): 419—422.
33. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19 (3): 615—623.
34. Cha SK, Ortega B, Kurosu H et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galec-tin-1. Proc Natl Acad Sci USA 2008; 105 (28): 9805—9810.
35. Drueke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int. 2010; 78 (11): 1057—1060.
36. Imura A, Tsuji Y, Murata M et al. a-Klotho as a regulator of calcium homeostasis. Science 2007; 316 (5831): 1615—1618.
37. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24 (9): 3438—3450.
38. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22 (1): 124—136.
39. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280 (4): 1015—1020.
40. O’Brien SP, Boulanger JH, Liu S et al. Decline in Klotho expression precedes FGF23 and PTH induction in the Jck mouse, a progressive genetic model of CKD-MBD [Abstract F-FC224]. J Am Soc Nephrol 2009; 20: 54A.
41. Kuro-o М. Phosphate and Klotho. Kidney International 2011; 79 (Suppl 121), S20—S23.
42. Sitara D, Razzaque MS, St-Arnaud R et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006; 169 (6): 2161—2170.
43. Ohnishi M, Nakatani T, Lanske B et al. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009; 75 (11): 1166—1172.
44. Morishita K, Shirai A, Kubota M et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131 (12): 3182—3188.
45. Stubbs JR, Liu S, Tang W et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18 (7): 2116—2124.
46. Ohnishi M, Nakatani T, Lanske B et al. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2009; 2 (6): 583—590.
47. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77 (3): 211—218.
48. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77 (3): 232—238.
49. Krajisnik T, Olauson H, Mirza MA et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010; 78 (10): 1024—1032.
50. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125—131.
51. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117 (9): 2684—2691.
52. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78 (11): 1119—1127.
53. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. CJASN 2010; 5 (1): 110—116.
54. Dusso AS, Pavlopoulos T, Naumovich L et al. p21WAF1 and transforming growth factor-б mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001; 59 (3): 855—865.
55. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637—643.
56. Cozzolino M, Lu Y Sato T et al. A critical role for enhanced TGF-a and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 2005; 289 (5): F1096—F1102.
57. Raught B, Gingras AC, James A et al. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996; 56 (19): 4382—4386.
58. Arcidiacono MV, Sato T, Alvarez-Hernandez D et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 2008; 19 (2): 310—320.
59. Dusso A, Arcidiacono MV, Yang J et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121 (1-2): 193—198.
60. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104 (50): 19796—19801.
61. Bloch L, Sineshchekova O, Reichenbach D et al. Klotho is a substrate for a-, в- and г-secretase. FEBS Lett 2009; 583 (19): 3221—3224.
62. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104 (50): 19796—19801.
63. Cordero JB, Cozzolino M, Lu Y et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002; 277 (41): 38965—38971.
64. Dusso A. Kidney disease and vitamin D levels: 25-hydroxyvita-min D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int 2011; Suppl. 1: 136—141.
65. Tatsumi S, Segawa H, Morita K et al. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998; 139 (4):1692—1699.
66. Jiang Y, Wang M. Overexpression of parathyroid pituitary-specific transcription factor (Pit)-1 in hyperphosphatemia-induced hyperparathyroidism of chronic renal failure rats. Chin Med J (Engl) 2010;123 (12): 1566—1570.
67. Fliser D, Kollerits B, Never U et al. Fibroblast growth factor 23 (FGF-23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18 (9): 2600—2608.
68. Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2010; 6 (2): 241—247.
69. Vervloet M, van Zuilen AD, Blankenstijn PJ et al. Fibroblast growth factor 23 is associated with proteinuria. J Am Soc Nephrol 2010; 21: 186A.
70. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359 (6): 584—592.
71. Vervloet M, Larsson T. Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney Int 2011; Suppl. 1: 130—135.
72. Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205 (2): 385—390.
73. Mirza MA, Hansen T, Johansson L et al. Relationship between circulating FGF-23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24 (10): 3125—3131.
74. Yilmaz MI, Sonmez A, Saglam M et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78 (7): 679—685.
75. Kirkpantur A, Balci M, Gurbuz CA et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haeodialysis patients. Nephrol Dial Transplant 2011; 26 (4): 1346—1354.
76. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 2008; 389 (3): 233—241.
77. Kusaba T, Okigawa M, Matui A et al. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA 2010; 107 (45): 19308—19313.
78. Nagai R, Saito x Ohyama Y et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000; 57 (5): 738—746.
79. Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286 (10): 8655—8665.
80. Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 2004; 109 (14): 1776—1782.
81. Maschio G, Tessitore N, D’Angelo A et al. Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy. Am J Clin Nutr 1980; 33 (7): 1546—1554.
82. Alfrey AC: Effect of dietary phosphate restriction on renal function and deterioration. Am J Clin Nutr 1988; 47 (1): 153—156.
Review
For citations:
Ilin A.V., Arbuzova M.I. FIBROBLAST GROWTH FACTOR 23 AND KLOTHO PROTEIN IN THE PATHOGENESIS OF SECONDARY HYPERPARATHYROIDISM. Osteoporosis and Bone Diseases. 2013;16(3):20-27. (In Russ.) https://doi.org/10.14341/osteo2013320-27
Views:
3226
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
